Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with R/R EBV+ PTCL Announced April 16, 2024
Three-Year Follow-up Data in BCG-Unresponsive NMIBC Show Durable Response to Treatment with ADSTILADRIN (nadofaragene firadenovec-vncg) in 2 Patient Cohorts April 16, 2024
Initial Data Reported from Clinical Study Evaluating ME-344 + Avastin in Relapsed Metastatic CRC Patients April 16, 2024
Positive Preliminary PFS and Long-term ctDNA Data from Ph 2 Portion of Ongoing Ph 2/3 Study of Personalized Cancer Vaccine, GRANITE, in 1L Metastatic MSS-CRC announced April 8, 2024
Imfinzi significantly improved OS and PFS for patients with limited-stage SCLC in ADRIATIC Ph 3 trial April 8, 2024
Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML published in Leukemia & Lymphoma April 8, 2024
Positive Surveillance Analysis from the Randomized Ph 3 IMvigor011 Trial in MIBC announced April 8, 2024
Positive Interim Data Announced from Randomized Ph 2 Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer April 8, 2024
FAILED TRIAL: Topline Results of Ph 2 KICKSTART Trial of Tomivosertib + Pembrolizumab in NSCLC announced April 8, 2024
Positive Ph 1/2 Data for GT-30 Trial of Personalized Therapeutic Cancer Vaccine Announced April 8, 2024
METIS Ph 3 Trial Met Primary Endpoint of Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Mets from NSCLC April 2, 2024
KRYSTAL-12 Trial of KRAZATI (adagrasib) Meets Primary Endpoint of PFS for Patients with Pretreated KRAS G12C-Mutated NSCLC April 2, 2024
Tagrisso + chemo showed favourable trend in OS in EGFR-mutated advanced lung cancer with further follow-up in FLAURA2 Ph 3 trial March 26, 2024
FAILED TRIAL: Ph 3 KEYLYNK-006 trial of KEYTRUDA + maintenance LYNPARZA did not meet dual primary endpoints of OS and PFS in 1L EGFR/ALK/ROS1 WT patients with metastatic nonsquamous NSCLC March 26, 2024
Positive Topline Results Announced from Ph 1 Portion of Ph 1/2a Trial of IMM-1-104 in RAS-Mutant Solid Tumors March 26, 2024
Positive Findings announced from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research March 26, 2024
Additional Positive Data announced from Ph 1 Part of BEXMAB Study in Both Higher-Risk HMA-Failed MDS and R/R AML March 26, 2024
CheckMate -9DW Trial of Opdivo + Yervoy Meets Primary Endpoint of OS for the 1L Treatment of Advanced HCC March 26, 2024
Lynparza and Imfinzi demonstrated strong clinical benefit and more than doubled median duration of response vs. chemo in patients with MMR-proficient advanced or recurrent endometrial cancer March 26, 2024
KEYTRUDA + CRT Significantly Improved OS Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer March 18, 2024
Mosunetuzumab Achieved Primary Endpoint in Expansion Cohort of Japanese Ph 1 study for R/R Follicular Lymphoma March 18, 2024
New clinical data from 2L ONSEMBLE trial provides further evidence of the efficacy of onvansertib + FOLFIRI/bev in bev naïve RAS-mutated mCRC patients March 12, 2024
Positive results announced from DREAMM-8 Ph 3 trial for Blenrep versus SoC combo in R/R multiple myeloma March 12, 2024
